Dr. White is a consultant to the pharmaceutical industry. After a Ph.D. and post-doctoral fellowship at Oxford, he began a career in infectious disease drug discovery. He has over 28 years of experience in the pharmaceutical industry holding positions Glaxo, Lederle and Bristol-Myers Squibb (BMS). At BMS, he was Vice President in charge of Infectious Disease Drug Discovery and was involved with the development of the cephalosporins cefepime and cefprozil. Following this, Dr. White accepted a position at Versicor, where he became Chief Scientific Officer. He was involved in the licensing and development of dalbavancin and anidulafungin, and in taking Versicor public. His expertise concerns the mechanism of action of and resistance to antimicrobial drugs. He received his undergraduate degree in Biochemistry from the University of Manchester, and a Ph.D. in Microbial Biochemistry from the University of Oxford.